Download PDF
Thromb Haemost 2007; 98(02): 473-474
DOI: 10.1160/TH07-02-0131
Case Report
Schattauer GmbH

Retinal central artery occlusion in a young woman after ten days of a drospirenone-containing oral contraceptive (Yasmin)

Antonio Girolami
1   Department of Medical and Surgical Sciences, Padua University, Padua, Italy
,
Silvia Vettore
1   Department of Medical and Surgical Sciences, Padua University, Padua, Italy
,
Fabiana Tezza
1   Department of Medical and Surgical Sciences, Padua University, Padua, Italy
,
Bruno Girolami
2   Medicina Generale, Azienda Ospedaliera Padova, Padova, Italy
› Author Affiliations
Further Information

Publication History

Received 21 February 2007

Accepted after resubmission 30 April 2007

Publication Date:
28 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Oelkers W. Drospirenone. A new progestogen with antimineralcorticoid activity, resembling natural progesterone. Eur J Contracept Reprod Health Care 2000; 5 (Suppl. 03) 17-24.
    PubMedGoogle Scholar
  • 2 Heinemann LA, Dinger J. Safety of a new oral contraceptive containing drospirenone. Drug Saf 2004; 27: 1001-1018.
    CrossrefPubMedGoogle Scholar
  • 3 Thorneycroft IH. Yasmin: the reason why. Eur J Contracept Reprod Health Care 2002; 7 (Suppl. 03) 13-18.
    CrossrefPubMedGoogle Scholar
  • 4 Pearce HM, Layton D, Wilton LW. et al. Deeep vein thrombosis and pulmonary embolism reported in the prescription event monitoring study of Yasmin. Brit J Clin Pharmac 2005; 60: 98-102.
    PubMedGoogle Scholar
  • 5 Van Grootheest K, Vrieling T. Thromboembolism associated with the new contraceptive Yasmin. Brit Med J 2003; 326: 257-257.
    CrossrefPubMedGoogle Scholar
  • 6 Sheldon P. Dutch GPs warned against new contraceptive pill. Br Med J 2002; 324: 869.
    CrossrefPubMedGoogle Scholar
  • 7 Vandenbroucke JP, Rosing J, Bloemenkamp KW. et al. Oral contraceptives and risk of venous thrombosis. New Eng J Med 2001; 344: 1527-1535.
    CrossrefPubMedGoogle Scholar
  • 8 Vayà A, Mira Y, Ferrando F. et al. Transient ischemic attack associated with the new contraceptive Yasmin. Thromb Res 2003; 112: 121-123.
    CrossrefPubMedGoogle Scholar
  • 9 Cabou C, Lacroix I, Roncalli J. et al. Infarctus du myocarde chez une jeune femme fumeuse sous contraception orale. Arch Moe Coeur Vaiss 2006; 99: 80-85.
    PubMedGoogle Scholar
  • 10 Girolami A, Stevanato F, Lazzaro AR. Bilateral ileofemoral thrombophlebitis after 10 contraceptive pills in a 24-year old woman with antithrombin deficiency. Acta Hematol 1988; 79: 118-119.
    CrossrefPubMedGoogle Scholar
  • 11 Girolami A, Simioni P, Sartori MT. et al. Oral contraceptives caused thrombosis in a monoclonal twin with protein C deficiency while the other without medication remained asymptomatic. Blood Coag Fibrinolysis 1992; 3: 119-120.
    CrossrefPubMedGoogle Scholar
  • 12 Kemmeren JM, Tanis BC, vander Bosh MA. et al. Risk of arterial thrombosis in relation to oral contraception (ratio) study: oral contraceptives and the risk of ischemic stroke. Stroke 2002; 33: 1202-1208.
    CrossrefPubMedGoogle Scholar
  • 13 Tanis BC, der Bosch MA, Kemmeren JM. et al. Oral contraceptives and risk of myocardial infarction. New Eng J Med 2001; 345: 1787-1793.
    CrossrefPubMedGoogle Scholar
  • 14 Van Vliet HA, Winkel TA, Noort I. et al. Prothrombotic changes in users of combined contraceptives containing drospirenone and cyprotenone acetate. J Thromb Haemost 2004; 2: 2060-2062.
    CrossrefPubMedGoogle Scholar
  • 15 Chasan-Taber L, Stampfer M. Oral contraceptives and myocardial infarction. The search for the smoking gun. New Eng J Med 2001; 345: 1841-1842.
    CrossrefPubMedGoogle Scholar